To the Editor We read the recent article by Glassman and Melia1 with great interest. The authors recommend that careful consideration should be given in ophthalmic clinical trials to enrollment of both eyes when possible and highlight aspects of study design to consider. We support these recommendations but also strongly advise consideration of 2 additional aspects of study design when considering whether the methods should involve randomization of 1 eye or 2 eyes.